Sinclair Dermatology Pty Ltd   Report issue

Academic/Hospital Phase 2
Founded: East Melbourne Australia

Organization Overview

First Clinical Trial
2015
NCT02550678
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

fluorouracil (efudex) (1 trial)

Gusacitinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Basal Cell Nevus Syndrome (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Basal Cell (Phase 2)

Skin Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2